Successful treatment of COVID-19 induced neutrophilic myositis with intravenous immunoglobulin and corticosteroids: a case report
Neutrophilic myositis (NM) is an inflammatory disorder predominantly characterized by neutrophilic infiltration in the muscles, which is suggested to be an extracutaneous manifestation of neutrophilic dermatosis (ND). NM is a rare disorder which has been occasionally reported in association with hematologic and inflammatory disorders. This case report describes a 45-year-old woman who presented with gradual muscle weakness developed after coronavirus disease 2019 (COVID-19) infection. Electromyography and nerve conduction velocity findings were compatible with inflammatory myopathy and muscle biopsy revealed neutrophilic infiltration. She was successfully treated with intravenous immunoglobulin, prednisolone 1 mg/kg/day and azathioprine 150 mg/day. In conclusion, the COVID-19 infection itself and the drugs used to treat it can cause a number of muscle disorders. Awareness of muscular involvement in COVID-19 infected patients is important for early diagnosis and appropriate treatment..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Reumatismo - 73(2022), 4 |
| Sprache: |
Englisch ; Italienisch |
|---|
| Beteiligte Personen: |
S. Assar [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.4081/reumatismo.2021.1437 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ044200544 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ044200544 | ||
| 003 | DE-627 | ||
| 005 | 20230308080423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4081/reumatismo.2021.1437 |2 doi | |
| 035 | |a (DE-627)DOAJ044200544 | ||
| 035 | |a (DE-599)DOAJ4ead4601ea3d4c3098f7fb9932c604c1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a ita | ||
| 050 | 0 | |a RC31-1245 | |
| 100 | 0 | |a S. Assar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful treatment of COVID-19 induced neutrophilic myositis with intravenous immunoglobulin and corticosteroids: a case report |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Neutrophilic myositis (NM) is an inflammatory disorder predominantly characterized by neutrophilic infiltration in the muscles, which is suggested to be an extracutaneous manifestation of neutrophilic dermatosis (ND). NM is a rare disorder which has been occasionally reported in association with hematologic and inflammatory disorders. This case report describes a 45-year-old woman who presented with gradual muscle weakness developed after coronavirus disease 2019 (COVID-19) infection. Electromyography and nerve conduction velocity findings were compatible with inflammatory myopathy and muscle biopsy revealed neutrophilic infiltration. She was successfully treated with intravenous immunoglobulin, prednisolone 1 mg/kg/day and azathioprine 150 mg/day. In conclusion, the COVID-19 infection itself and the drugs used to treat it can cause a number of muscle disorders. Awareness of muscular involvement in COVID-19 infected patients is important for early diagnosis and appropriate treatment. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a neutrophilic myositis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a intravenous immunoglobulins. | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Internal medicine | |
| 700 | 0 | |a M. Pournazari |e verfasserin |4 aut | |
| 700 | 0 | |a P. Soufivand |e verfasserin |4 aut | |
| 700 | 0 | |a D. Mohamadzadeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Reumatismo |d PAGEPress Publications, 2012 |g 73(2022), 4 |w (DE-627)DOAJ000058424 |x 22402683 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2022 |g number:4 |
| 856 | 4 | 0 | |u https://doi.org/10.4081/reumatismo.2021.1437 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4ead4601ea3d4c3098f7fb9932c604c1 |z kostenfrei |
| 856 | 4 | 0 | |u https://reumatismo.org/index.php/reuma/article/view/1437 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0048-7449 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2240-2683 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2022 |e 4 | ||